Sarah Injac

Sarah Injac has extensive experience in the field of pediatric hematology oncology. Sarah started their career at Texas Children's Hospital in 2017 as a Pediatric Oncologist and worked there until 2021. During this time, they gained practical experience in treating pediatric cancer patients.

In 2011, Sarah joined Baylor College of Medicine as a Pediatric Resident and later transitioned to the role of Clinical Fellow in Pediatric Hematology Oncology. Sarah continued to advance in their career and became an Instructor in Pediatric Hematology Oncology. Finally, they served as an Assistant Professor, focusing on laboratory and early stage clinical research related to pediatric brain tumors.

Most recently, Sarah has joined Nurix Therapeutics in 2021 as a Medical Director. With their diverse experience in both clinical settings and research, they bring a unique perspective to their role in advancing medical treatments.

Overall, Sarah Injac has demonstrated a strong commitment to pediatric oncology through their work in hospitals, academia, and now in the field of therapeutics.

Sarah Injac earned their Bachelor of Arts (BA) degree in Biology from Columbia University in 2000. After that, they completed their Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology at The Rockefeller University from 2001 to 2007. Following their PhD, they pursued a Doctor of Medicine (MD) degree at Baylor College of Medicine from 2007 to 2011. Additionally, Sarah Injac holds certifications in General Pediatrics and Pediatric Hematology-Oncology from the American Board of Pediatrics (ABP).